TDI Pharmaceutical, WE’RE DEVELOPING TARGETED ALZHEIMER’S DISEASE TREATMENTS FOR PATIENTS TO HOLD ONTO THEIR MOMENTS – AND TO CREATE NEW ONES.
WHO IS TDI Pharmaceutical Sciences?
At TDI pharmaceutical, our aims and mission is to become a trusted source of safe and effective medication-based treatments to address the unmet needs for people suffering from neurodegenerative and Central nervous system diseases,or any form of neurological disorders.
WHAT IS AN AMYLOID-BETA OLIGOMER?
Toxic amyloid-beta oligomers (AβO) are soluble protein aggregates that accumulate in the brain. They are also shown to be a primary and persistent driver of Alzheimer’s-associated neurodegeneration.
HOW DOES ACU193 WORK?
We are advancing Donepezil, a therapy targeting AβO and designed to have disease-modifying benefits with an improved safety profile, while also potentially providing symptomatic benefit for Alzheimer’s patients.
